Thrombin-Antithrombin Complex

Assess thrombin formation and antithrombin consumption.

Traumatic venipuncture, prolonged stasis, or inadequate centrifuging may invalidate results. Inadequate mixing of the patient sample and the citrate in the collection tube may result in falsely elevated levels. TAT levels may be elevated secondary to inflammation and microvascular thrombosis in surgical patients or those patients in acute distress.

Thrombin-antithrombin complexes (TAT) form covalently following thrombin generation and have a plasma half-life of 10 to 15 minutes. The presence of TAT indicates ongoing thrombin formation and the consumption of antithrombin. Upon activation of coagulation, antithrombin complexes with thrombin as well as other serine proteases. Complex formation is greatly enhanced by the presence of heparin or other glycosaminoglycans. The reaction initially is reversible, but becomes irreversible following the formation of a covalent bond between antithrombin and thrombin. This binding results in complete inhibition of thrombin's activity. Elevated levels of TAT may be associated with advancing age, pregnancy, septicemia, disseminated intravascular coagulation, multiple trauma, acute pancreatitis, acute and chronic leukemia, preëclampsia, acute and chronic liver disease, and other predisposing causes of thrombosis. Increased levels are also reported during heparin and fibrinolytic therapy. TAT levels are markedly reduced in the first 24 hours after receiving oral anticoagulants. The TAT assay can detect the intravascular generation of thrombin and provides valuable information in the diagnosis of thrombotic events. Decreasing TAT levels can also indicate the resolution of a thrombotic event. A normal TAT level in the presence of an elevated D-dimer may indicate an old thrombus. Elevated TAT measurements may be accompanied by increased levels of prothrombin fragment 1+2, fibrinopeptide A, fibrin(ogen) degradation products, and D-dimer. D-dimer has greater sensitivity for detection of deep venous thrombosis.

1. Adcock DM, Kressin DC, Marlar RA. Effect of 3.2% vs 3.8% sodium citrate concentration on routine coagulation testing. Am J Clin Pathol. 1997 Jan; 107(1):105-110. PubMed 8980376

2. Reneke J, Etzell J, Leslie S, Ng VL, Gottfried EL. Prolonged prothrombin time and activated partial thromboplastin time due to underfilled specimen tubes with 109 mmol/L (3.2%) citrate anticoagulant. Am J Clin Pathol. 1998 Jun; 109(6):754-757. PubMed 9620035

3. National Committee for Clinical Laboratory Standardization. Collection, Transport, and Processing of Blood Specimens for Coagulation Testing and General Performance of Coagulation Assays; Approved Guideline. 5th ed. Villanova, Pa: NCCLS; 2008. Document H21-A5:28(5).

4. Gottfried EL, Adachi MM. Prothrombin time and activated partial thromboplastin time can be performed on the first tube. Am J Clin Pathol. 1997 Jun; 107(6):681-683. PubMed 9169665

5. McGlasson DL, More L, Best HA, Norris WL, Doe RH, Ray H. Drawing specimens for coagulation testing: Is a second tube necessary? Clin Lab Sci. 1999 May-Jun; 12(3):137-139. PubMed 10539100

Boisclair MD, Lane DA, Wilde JT, Ireland H, Preston FE, Ofosu FA. A comparative evaluation of assays for markers of activated coagulation and/or fibrinolysis: Thrombin-antithrombin complex, D-dimer, and fibrinogen/fibrin fragment E antigen. Br J Haematol. 1990 Apr; 74(4):471-479. PubMed 2189490

Boneu B, Bes G, Pelzer H, Sié P, Boccalon H. D-Dimer, thrombin antithrombin III complexes, and prothrombin fragments 1+2: Diagnostic value in clinically suspected deep vein thrombosis. Thromb Haemost. 1991 Jan 23; 65(1):28-31. PubMed 2024237

Fareed J, Hoppensteadt DA, Leya F, Iqbal O, Wolf H, Bick R. Useful laboratory tests for studying thrombogenesis in acute cardiac syndromes. Clin Chem. 1998 Aug; 44(8 Pt 2):1845-1853. PubMed 9702994

Speiser W, Mallek R, Koppensteiner R, et al. D-Dimer and TAT measurement in patients with deep venous thrombosis: Utility in diagnosis and judgment of anticoagulant treatment effectiveness. Thromb Haemost. 1990 Oct 22; 64(2):196-201. PubMed 2125371